GLP-1 receptor agonists consistently demonstrated renal protective effects, primarily driven by reductions in new or worsening nephropathy and macroalbuminuria, with more modest and inconsistent effects on estimated glomerular filtration rate (eGFR) decline. This evidence concerns the gene GLP1R and kidney disorder.